Navigation Links
Study favors as-needed treatment over maintenance therapy for patients with follicular lymphoma
Date:12/12/2011

(SAN DIEGO, December 11, 2011) Asymptomatic patients diagnosed with nonbulky follicular lymphoma, a slow-growing type of non-Hodgkin lymphoma, have traditionally been watched for signs or symptoms of disease progression and then treated with a combination of rituximab and chemotherapy or rituximab alone for select cases. Recent trials have suggested a role for treatment of asymptomatic patients with single-agent rituximab followed by additional periodic dosing, called "maintenance therapy." However, new research suggests that these patients may have similar success rates simply with as-needed treatment. Results from the study will be presented today at the 53rd Annual Meeting of the American Society of Hematology.

"Current research aims to ensure that we are not only giving our patients the best possible chance to live long, healthy lives after their cancer diagnoses, but also improving their quality of life while reducing their health-care costs," said Jane N. Winter, MD, moderator of the press conference and Professor of Medicine in the Division of Hematology-Oncology at Northwestern University Feinberg School of Medicine in Chicago. "If we can limit the frequency of treatment or reduce the need for chemotherapy and still maintain good outcomes, we can reduce some of the burdens on both the patients and the health care community."

This press conference will take place on Sunday, December 11, at 8:00 a.m. PST.

Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma [LBA-6]

Results from a study evaluating two different strategies for management of asymptomatic low-tumor-burden (LTB) follicular lymphoma (FL) patients found that, following an induction course of rituximab, repeated treatment with the therapy at time of progression is just as effective in managing the disease as ongoing maintenance therapy.

Historically, patients with LTB (defined as small tumor size, limited lymph node involvement, limited or no symptoms, and other factors) disease have been observed rather than treated, with treatment deferred until the patient was symptomatic or the disease progressed, risking the individual's well-being. This has been called the "watch and wait" strategy, which allows physicians to delay chemotherapy treatment for their patients for three years or more. Researchers have hypothesized that rituximab could delay the need for chemotherapy and that maintenance rituximab (MR) would provide disease control superior to rituximab retreatment (RR) when the disease progressed. In order to evaluate the two different rituximab dosing strategies for LTB follicular lymphoma, researchers embarked on the Eastern Cooperative Oncology Group Protocol E4402 (RESORT), a randomized, Phase III clinical trial.

The primary endpoint was time to treatment failure (TTTF), defined as disease that progresses within six months of the last rituximab treatment, disease that doesn't respond to therapy, need for alternative therapy, or inability to complete the treatment protocol. Secondary endpoints included time to first chemotherapy, quality of life (QOL), and safety.

The RESORT trial compared the treatment strategies for 384 patients with previously untreated LTB FL. All patients received rituximab for four weeks, and the 274 patients who achieved a complete or partial response were then randomized to MR (single dose of rituximab every three months, n=140) or RR (four weekly doses of rituximab at disease progression, n=134). Patients were evaluated every three months and were followed until treatment failure. The average number of total doses in the MR arm was 15.8 per patient versus 4.5 doses per patient in the RR arm.

The analysis showed that TTTF was 3.9 years for MR-treated FL patients versus 3.6 years for RR-treated patients, rates longer than historical "watch and wait" strategies in this population. At three years of follow-up, 95 percent of MR patients had avoided cytotoxic therapy, as compared with 86 percent of RR patients. Less than 5 percent of patients in the trial experienced any severe hematologic or non-hematologic toxicities. At 12 months after randomization, there was no discernible difference in health-related quality of life or burden of stress between the two study arms.

"In summary, our study found no significant difference between administering maintenance therapy and re-treating with rituximab as needed for this patient population. In addition, given the significant difference in total doses administered, re-treatment with rituximab is less costly than rituximab maintenance therapy," said lead author Brad S. Kahl, MD, Assistant Professor of Medicine at the University of Wisconsin in Madison, Wis. "We believe the re-treatment strategy is the preferred option to help patients with low-tumor-burden FL manage their disease."

Dr. Kahl will present this study in the Late-Breaking Abstracts Session on Tuesday, December 13, at 7:30 a.m. PST at the San Diego Convention Center in Hall AB.


'/>"/>

Contact: Lindsey Love
llove@hematology.org
202-552-4925
American Society of Hematology
Source:Eurekalert

Related medicine news :

1. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
2. American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time
3. TV drama can be more persuasive than news program, study finds
4. Study carried out into biological risks of eating reptiles
5. Neuroimaging study may pave way for effective Alzheimers treatments
6. Study finds racial gaps continue in heart disease awareness
7. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
8. First blinded study of venous insufficiency prevalence in MS shows promising results
9. Soothing infants with food focus of childhood obesity study
10. People with anxiety disorder less able to regulate response to negative emotions, study shows
11. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... ... distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in ... and patient safety. Only a few hospitals and facilities have earned this distinction. ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for Input ... JMIR Medical Informatics . , Results of the comparative usability study demonstrate that ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... CURE Media ... centers and advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat ... the announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to team ...
(Date:12/8/2016)... ... ... Fitness Camp (PFC) and The Chopra Center for Wellbeing announced today the launch of ... headquarters of Omni La Costa Resort & Spa in San Diego. , Chopra FIT ... development, a healthy lifestyle, or mental and physical healing. The week-long wellness program combines ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... and development solutions for drugs, biologics and consumer health products, today announced that ... set up in 2006 as a non-profit organization to unite pharmaceutical and healthcare ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... QUEBEC CITY , Dec. 8, 2016 /PRNewswire/ ... key US patents for improving the accuracy, reproducibility ... CD images in long and small bone orthopaedic ... proprietary approach to creating personalized orthopaedic restorations based ... create personalized orthopaedic restorations, the company harnesses the ...
(Date:12/8/2016)... , Dec. 8, 2016  A new study ... that the use of opioid therapy to treat chronic ... the likelihood of more harmful consequences, including death. ... M.D., and Zankhana Mehta , M.D., authored the ... on chronic opioid therapy. The study was published in ...
(Date:12/8/2016)... 2016 Information products and services provider ... Scopus , the world,s largest abstract and citation database of ... for journals from over 5,000 publishers. The new set of metrics ... to and when to adjust a journal,s editorial strategy. ... , , ...
Breaking Medicine Technology: